dc.contributor.author | Osman, E. | |
dc.contributor.author | Daniel, O. | |
dc.contributor.author | Ogiri, S. | |
dc.contributor.author | Awe, A. | |
dc.contributor.author | Obasanya, O. | |
dc.contributor.author | Adebiyi, E. | |
dc.contributor.author | Ige, O. | |
dc.contributor.author | Oladimeji, O. | |
dc.contributor.author | Dairo, O. G. | |
dc.contributor.author | Declercq, E. | |
dc.contributor.author | Gumusboga, M. | |
dc.contributor.author | Akang, G. | |
dc.contributor.author | Bakare, R. A. | |
dc.date.accessioned | 2012-12-21T13:55:27Z | |
dc.date.available | 2012-12-21T13:55:27Z | |
dc.date.issued | 2012 | |
dc.identifier.issn | 2161-105X | |
dc.identifier.doi | http://dx.doi.org/10.4172/2161-105X.S6-001 | |
dc.identifier.other | ITG-B11B | |
dc.identifier.other | DBM | |
dc.identifier.other | U-MYCOB | |
dc.identifier.other | DOI | |
dc.identifier.other | FTA | |
dc.identifier.other | E-only | |
dc.identifier.other | UPD53 | |
dc.identifier.uri | http://hdl.handle.net/10390/7272 | |
dc.language | English | en |
dc.subject | Bacterial diseases | en |
dc.subject | Tuberculosis | en |
dc.subject | Mycobacterium tuberculosis | en |
dc.subject | Multidrug resistance | en |
dc.subject | First-line drugs | en |
dc.subject | Second-line drugs | en |
dc.subject | Treatment failure | en |
dc.subject | Isoniazid | en |
dc.subject | Rifampicin | en |
dc.subject | Ethambutol | en |
dc.subject | Streptomycin | en |
dc.subject | Pyrazinamide | en |
dc.subject | Kanamycin | en |
dc.subject | Cycloserine | en |
dc.subject | Ofloxacin | en |
dc.subject | Prothionamide | en |
dc.subject | Ethionamide | en |
dc.subject | Nigeria | en |
dc.subject | Africa, West | en |
dc.title | Resistance of Mycobacterium tuberculosis to first and second line anti tuberculosis drugs in south west, Nigeria | en |
dc.type | Article-E | en |
dc.citation.issue | 001 | en |
dc.citation.jtitle | Pulmonary and Respiratory Medicine | en |
dc.citation.volume | S6 | en |
dc.citation.jabbreviation | Pulm Respirat Med | en |